• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Harmony Biosciences Holdings, Inc. - Common Stock (NQ:HRMY)

    28.51 +0.32 (+1.14%)
    Streaming Delayed Price Updated: 11:13 AM EST, Feb 26, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Press Releases about Harmony Biosciences Holdings, Inc. - Common Stock

    < Previous 1 2 3 Next >
    News headline image
    Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Beacon Biosignals Announces Partnership with Harmony Biosciences to Advance Objective Clinical Endpoints in Hypersomnia Conditions Through Quantitative EEG
    From Beacon Biosignals
    Via GlobeNewswire
    News headline image
    Harmony Biosciences Presents Clinically Meaningful Open-Label Extension Study Effectiveness Data for EPX-100 in Dravet Syndrome
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Present New Open-Label Extension Data from Phase 3 ARGUS Trial at the 2025 American Epilepsy Society Annual Meeting
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Announces Positive Results From the Pivotal Bioequivalence Study for Pitolisant Gastro-Resistant Formulation
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Announces Initiation of First-In-Human Study With Potential Best-In-Class Orexin 2 Receptor Agonist (BP1.15205) for Central Disorders of Hypersomnolence
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Participate in Upcoming Investor Conferences
    From Harmony Biosciences
    Via Business Wire
    News headline image
    Harmony Biosciences Reports Strong Q3 2025 Financial Results; Recently Raised 2025 Revenue Guidance to $845-$865M
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Preannounces Strong Q3 2025 WAKIX Performance; Raises 2025 Revenue Guidance
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Provides Update From Its Phase 3 RECONNECT Study of ZYN002 in Fragile X Syndrome
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Present Rare Epilepsy Data at the 36th International Epilepsy Congress
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Participate in 2025 Cantor Global Healthcare Conference
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Reports Strong Q2 2025 Financial Results and Reaffirms 2025 Revenue Guidance; On Track to Announce Fragile X Topline Data From Phase 3 Registrational Trial in Q3 2025
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Participate in H.C. Wainwright "HCW@Home" Series
    From Harmony Biosciences
    Via Business Wire
    News headline image
    Harmony Biosciences Presents Preclinical Data Demonstrating Significant Wake-Promoting and Cataplexy-Suppressing Effects of BP1.15205 in Narcolepsy at SLEEP 2025
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Strengthens Patent Position With Favorable Settlement in ANDA Litigation
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Participate in Goldman Sachs 46th Annual Global Healthcare Conference
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Reports Strong Q1 2025 Financial Results, Highlights Advancement of Its Pipeline and Upcoming Catalysts, and Reaffirms 2025 Revenue Guidance ​
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Report First Quarter 2025 Financial Results on May 6, 2025
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Presents Promising Open-Label Extension Data of ZYN002 in Fragile X Syndrome
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences to Participate in 24th Annual Needham Virtual Healthcare Conference
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Names Adam Zaeske as Chief Commercial Officer to Lead the Next Phase of Commercial Growth as Its Portfolio Expands
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    HRMY Investors Have Opportunity to Join Harmony Biosciences Holdings, Inc. Fraud Investigation with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    Harmony Biosciences to Participate in Upcoming Investor Conferences
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    News headline image
    Harmony Biosciences Reports Strong 2024 Financial Results and Reiterates 2025 Net Revenue Guidance; Highlights 2025 Catalysts in Sleep/Wake and Fragile X Syndrome Development Programs
    From Harmony Biosciences Holdings, Inc.
    Via Business Wire
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.